Radiosensitivity in patients affected by ARPC1B deficiency: a new disease trait?

ARPC1B DNA damage response (DDR) combined immunodeficiency immune dysregulation radiosensitivity

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 13 04 2022
accepted: 30 06 2022
entrez: 15 8 2022
pubmed: 16 8 2022
medline: 17 8 2022
Statut: epublish

Résumé

Actin-related protein 2/3 complex subunit 1B (ARPC1B) deficiency is a recently described inborn error of immunity (IEI) presenting with combined immunodeficiency and characterized by recurrent infections and thrombocytopenia. Manifestations of immune dysregulation, including colitis, vasculitis, and severe dermatitis, associated with eosinophilia, hyper-IgA, and hyper-IgE are also described in ARPC1B-deficient patients. To date, hematopoietic stem cell transplantation seems to be the only curative option for patients. ARPC1B is part of the actin-related protein 2/3 complex (Arp2/3) and cooperates with the Wiskott-Aldrich syndrome protein (WASp) in the regulation of the actin cytoskeleton remodeling and in driving double-strand break clustering for homology-directed repair. In this study, we aimed to investigate radiosensitivity (RS) in ARPC1B-deficient patients to assess whether it can be considered an additional disease trait. First, we performed trio-based next-generation-sequencing studies to obtain the ARPC1B molecular diagnosis in our index case characterized by increased RS, and then we confirmed, using three different methods, an increment of radiosensitivity in all enrolled ARPC1B-deficient patients. In particular, higher levels of chromatid-type aberrations and γH2AX foci, with an increased number of cells arrested in the G2/M-phase of the cell cycle, were found in patients' cells after ionizing radiation exposition and radiomimetic bleomycin treatment. Overall, our data suggest increased radiosensitivity as an additional trait in ARPC1B deficiency and support the necessity to investigate this feature in ARPC1B patients as well as in other IEI with cytoskeleton defects to address specific clinical follow-up and optimize therapeutic interventions.

Identifiants

pubmed: 35967303
doi: 10.3389/fimmu.2022.919237
pmc: PMC9372879
doi:

Substances chimiques

ARPC1B protein, human 0
Actin-Related Protein 2 0
Actin-Related Protein 2-3 Complex 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

919237

Informations de copyright

Copyright © 2022 Chiriaco, Ursu, Amodio, Cotugno, Volpi, Berardinelli, Pizzi, Cifaldi, Zoccolillo, Prigione, Di Cesare, Giancotta, Anastasio, Rivalta, Pacillo, Zangari, Fiocchi, Diociaiuti, Bruselles, Pantaleoni, Ciolfi, D’Oria, Palumbo, Gattorno, El Hachem, de Villartay, Finocchi, Palma, Rossi, Tartaglia, Aiuti, Antoccia, Di Matteo and Cancrini.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer VB declared a shared affiliation with the author J-PV to the handling editor at the time of review.

Références

Ann Ist Super Sanita. 2009;45(3):265-71
pubmed: 19861731
Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):510-6
pubmed: 19858715
J Cell Biol. 2010 Jul 12;190(1):101-14
pubmed: 20603326
Cell Rep. 2021 Jul 6;36(1):109318
pubmed: 34233185
J Allergy Clin Immunol. 2019 Jan;143(1):325-334.e2
pubmed: 29906526
Int J Mol Sci. 2021 Jul 02;22(13):
pubmed: 34281212
Blood. 2018 Nov 29;132(22):2362-2374
pubmed: 30254128
Nature. 2018 Jul;559(7712):61-66
pubmed: 29925947
Sci Rep. 2019 Jun 4;9(1):8255
pubmed: 31164689
Immunol Rev. 2013 Nov;256(1):282-99
pubmed: 24117828
J Cell Biol. 2019 Feb 4;218(2):422-432
pubmed: 30602538
Front Immunol. 2021 Jan 07;11:604206
pubmed: 33488606
Int J Mol Sci. 2020 Jan 10;21(2):
pubmed: 31936707
JCI Insight. 2021 Dec 8;6(23):
pubmed: 34673575
Transl Cancer Res. 2013;2(3):107-129
pubmed: 24058901
Nat Commun. 2017 Apr 03;8:14816
pubmed: 28368018
Front Immunol. 2021 Feb 19;12:634313
pubmed: 33679784
J Immunol. 2017 Dec 15;199(12):4036-4045
pubmed: 29127144
Cell Cycle. 2012 Nov 15;11(22):4129-34
pubmed: 23032308
Immunol Cell Biol. 2019 Apr;97(4):389-402
pubmed: 30779216
J Allergy Clin Immunol. 2019 Jun;143(6):2296-2299
pubmed: 30771411
Mutat Res. 2020 May - Dec;821:111716
pubmed: 32738522
J Allergy Clin Immunol. 2017 Jul;140(1):273-277.e10
pubmed: 27965109
Oncogene. 2019 Feb;38(6):852-867
pubmed: 30177840
Mutat Res. 2008 Nov 17;657(1):1-2
pubmed: 18793751
Mutat Res. 2012 Aug 1;736(1-2):39-47
pubmed: 21651917
Curr Opin Pediatr. 2013 Aug;25(4):474-9
pubmed: 23817304
J Innate Immun. 2021;13(1):3-25
pubmed: 32846417
Mutagenesis. 2013 Jul;28(4):465-73
pubmed: 23696313
J Allergy Clin Immunol. 2020 Jan;145(1):324-334
pubmed: 31604087
IUBMB Life. 2009 Jun;61(6):591-9
pubmed: 19472175

Auteurs

Maria Chiriaco (M)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Giorgiana Madalina Ursu (GM)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Donato Amodio (D)

Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Nicola Cotugno (N)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Stefano Volpi (S)

Center for Autoinflammatory Diseases and Immunodeficiencies, Scientific Institute for Research and Healthcare (IRCCS) Istituto Giannina Gaslini and University of Genoa, Genoa, Italy.

Francesco Berardinelli (F)

Laboratory of Neurodevelopment, Neurogenetics and Molecular Neurobiology, Scientific Institute for Research and Healthcare (IRCCS) Santa Lucia Foundation, Rome, Italy.
Department of Science, Roma Tre University, Rome, Italy.

Simone Pizzi (S)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Cristina Cifaldi (C)

Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Matteo Zoccolillo (M)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
San Raffaele Telethon Institute for Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), San Raffaele Scientific Institute, Milan, Italy.

Ignazia Prigione (I)

Center for Autoinflammatory Diseases and Immunodeficiencies, Scientific Institute for Research and Healthcare (IRCCS) Istituto Giannina Gaslini and University of Genoa, Genoa, Italy.

Silvia Di Cesare (S)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Carmela Giancotta (C)

Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Elisa Anastasio (E)

Department of Medical and Surgical Sciences, Pediatrics Unit, University "Magna Graecia", Catanzaro, Italy.

Beatrice Rivalta (B)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Lucia Pacillo (L)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Paola Zangari (P)

Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Alessandro G Fiocchi (AG)

Pediatric Allergology Unit, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Andrea Diociaiuti (A)

Dermatology Unit, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Alessandro Bruselles (A)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Francesca Pantaleoni (F)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Andrea Ciolfi (A)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Valentina D'Oria (V)

Research Laboratories, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Giuseppe Palumbo (G)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Haematology, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Marco Gattorno (M)

Center for Autoinflammatory Diseases and Immunodeficiencies, Scientific Institute for Research and Healthcare (IRCCS) Istituto Giannina Gaslini and University of Genoa, Genoa, Italy.

Maya El Hachem (M)

Dermatology Unit, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Jean-Pierre de Villartay (JP)

Université de Paris, Imagine Institute, Laboratory "Genome Dynamics in the Immune System", INSERM UMR 1163, F-75015, Paris, France.

Andrea Finocchi (A)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Paolo Palma (P)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Paolo Rossi (P)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.
Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.

Marco Tartaglia (M)

Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Alessandro Aiuti (A)

San Raffaele Telethon Institute for Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS), San Raffaele Scientific Institute, Milan, Italy.
Pediatric Immunohematology, San Raffaele Scientific Institute, Milan, Italy.
Vita Salute San Raffaele University, Milan, Italy.

Antonio Antoccia (A)

Department of Science, Roma Tre University, Rome, Italy.

Gigliola Di Matteo (G)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Caterina Cancrini (C)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Academic department of Pediatrics, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH